T2 Biosystems, Inc. (TTOO)

T2 Biosystems Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	7.18	7.19	22.31	28.06	18.13	8.34
Revenue Growth (YoY)	-58.15%	-67.75%	-20.50%	54.76%	117.52%	-20.62%
Cost of Revenue	15.57	15.36	21.01	20.7	21.28	16.76
Gross Profit	-8.39	-8.17	1.3	7.36	-3.15	-8.43
Selling, General & Admin	24.27	24.83	30.63	28.53	22.09	27.3
Research & Development	13.4	14.15	25.72	21.8	16.11	16.33
Other Operating Expenses	2.51	2.51	0.15	0	0	0
Operating Expenses	40.18	41.49	56.49	50.33	38.21	43.63
Operating Income	-48.58	-49.66	-55.2	-42.97	-41.36	-52.06
Interest Expense / Income	5	5.34	6.08	7.6	5.52	7.35
Other Expense / Income	-7.93	-4.93	0.72	-1.33	-0.08	-0.4
Pretax Income	-45.65	-50.08	-62	-49.24	-46.8	-59.01
Net Income	-45.65	-50.08	-62	-49.24	-46.8	-59.01
Preferred Dividends	0	0	0.33	0	0	0
Net Income Common	-45.65	-50.08	-62.33	-49.24	-46.8	-59.01
Shares Outstanding (Basic)	5	3	0	0	0	0
Shares Outstanding (Diluted)	5	3	0	0	0	0
Shares Change	3637.03%	5017.31%	60.53%	30.93%	166.60%	12.20%
EPS (Basic)	-11.51	-19.19	-1222.14	-1550.00	-1950.00	-6500.00
EPS (Diluted)	-11.51	-19.19	-1222.14	-1550.00	-1950.00	-6500.00
Free Cash Flow	-46.95	-48.33	-50.97	-39.33	-44.02	-46.12
Free Cash Flow Per Share	-9.21	-18.52	-999.31	-1238.00	-1813.83	-5067.49
Gross Margin	-116.97%	-113.58%	5.81%	26.21%	-17.37%	-101.12%
Operating Margin	-676.94%	-690.45%	-247.46%	-153.16%	-228.11%	-624.57%
Profit Margin	-636.09%	-696.19%	-279.46%	-175.50%	-258.12%	-707.93%
Free Cash Flow Margin	-654.28%	-671.88%	-228.50%	-140.19%	-242.77%	-553.35%
EBITDA	-38.59	-42.53	-53.65	-39.11	-38.12	-48.02
EBITDA Margin	-537.76%	-591.26%	-240.52%	-139.38%	-210.28%	-576.06%
Depreciation & Amortization	2.06	2.21	2.27	2.54	3.16	3.64
EBIT	-40.65	-44.73	-55.92	-41.65	-41.28	-51.66
EBIT Margin	-566.42%	-621.91%	-250.70%	-148.42%	-227.69%	-619.76%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).